Access through your institution
Buy or subscribe
The current debate on obesity pharmacotherapy is increasingly framed around a single question: which drug produces the greatest average weight loss? That question matters, but it is not always the most clinically useful one. With the arrival of second-generation anti-obesity medications, obesity care may benefit from a treat-to-target mindset, in which the aim is not simply to maximize weight reduction, but to define the amount of weight loss required to meaningfully alter a patient’s health trajectory [1].
At the same time, BMI is an imperfect surrogate for adiposity and health risk. The Lancet Diabetes & Endocrinology Commission on clinical obesity emphasized that BMI can both underestimate and overestimate adiposity and does not adequately define illness at the individual level [4]. Likewise, percent body fat may classify adiposity more directly than BMI in some populations [5]. <a href="https://healthylife7.com/the-best-exercise-for-your-personality-type-according-to-research/” title=”The Best Exercise for Your Personality Type, According to Research”>Accordingly, the BMI thresholds shown in Fig. 1 are intended as illustrative, pragmatic anchors rather than definitive treatment end points. The ultimate therapeutic target should be improvement in adiposity-related complications, symptoms, or functional risk.
This is a preview of subscription content, access
Access options
Access through your institution
- Purchase on SpringerLink
- Instant access to the full article PDF.
39,95 €
Prices may be subject to local taxes which are calculated during checkout
References
Garvey WT. New horizons. A new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab. 2022;107:e1339–e1347. https://doi.org/10.1210/clinem/dgab848
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. https://doi.org/10.1056/NEJMoa2032183
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393:26–36. https://doi.org/10.1056/NEJMoa2416394
Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221–62. https://doi.org/10.1016/S2213-8587(24)00316-4
Potter AW, Chin GC, Looney DP, Friedl KE. Defining overweight and obesity by percent body fat instead of body mass index. J Clin Endocrinol Metab. 2025;110:e1103–e1107. https://doi.org/10.1210/clinem/dgae341
Teede HJ, et al. Polyendocrine metabolic ovarian syndrome: new nomenclature for the condition previously known as polycystic ovary syndrome. Lancet. 2026. https://doi.org/10.1016/S0140-6736(26)00717-8
Yanovski SZ, Yanovski JA. Approach to obesity treatment in primary care: a review. JAMA Intern Med. 2024;184:818–29. https://doi.org/10.1001/jamainternmed.2023.8526
Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38:1655–79. https://doi.org/10.1093/humrep/dead156
Duah J, Seifer DB. Medical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review. Reprod Biol Endocrinol. 2025;23:2. https://doi.org/10.1186/s12958-024-01339-y
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32. https://doi.org/10.1056/NEJMoa2307563
Funding
The authors received no specific funding for this work
Author information
Authors and Affiliations
Department of Obstetrics and Gynecology, Hospital Quirónsalud Málaga, Málaga, Spain
Rodrigo Orozco
Clínica Palacios Málaga, Málaga, Spain
Rodrigo Orozco, Pablo Romero & Santiago Palacios
Clínica Palacios Almería, Almería, Spain
Pablo Romero & Santiago Palacios
Clínica Palacios Madrid, Madrid, Spain
Pablo Romero & Santiago Palacios
Authors
- Rodrigo OrozcoView author publications
Search author on:PubMed Google Scholar
- Pablo RomeroView author publications
Search author on:PubMed Google Scholar
- Santiago PalaciosView author publications
Search author on:PubMed Google Scholar
Contributions
RO conceived the manuscript, developed the conceptual framework, drafted the initial manuscript, and coordinated revisions. PR and SP contributed to conceptual development, interpretation of the literature, and critical revision of the manuscript for important intellectual content. All authors approved the final version of the manuscript
Ethics declarations
Competing interests
The authors declare that they have no known financial or personal relationships, commercial affiliations, advisory roles, stock ownership, honoraria, patent interests, or other competing interests that could have appeared to influence the work reported in this manuscript. No conflicts of interest are declared by Rodrigo Orozco, Pablo Romero, or Santiago Palacios in relation to this submission
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law
About this article
Cite this article
Orozco, R., Romero, P. & Palacios, S. From maximal weight loss to required weight loss: a call to action for weight management in gynecologic practice.
Int J Obes (2026). https://doi.org/10.1038/s41366-026-02166-4
Received:17 March 2026
Revised:11 June 2026
Accepted:05 July 2026
Published:11 July 2026
Version of record:11 July 2026
DOI
:https://doi.org/10.1038/s41366-026-02166-4
